Overview
- Researchers at Tufts, working with Manus Bio and Kcat Enzymatic, inserted a slime-mold enzyme called Gal1P into E. coli to convert glucose into tagatose.
- The new biosynthetic sequence reached about 95% conversion in lab tests, outperforming earlier routes that delivered roughly 40–77% yields.
- Tagatose provides about 92% of sucrose’s sweetness with roughly one-third the calories and shows minimal effects on blood glucose and insulin.
- The sweetener functions as a bulk ingredient that browns in baking, is considered tooth-friendly, and early research points to possible microbiome benefits.
- Tagatose holds FDA GRAS status, though scale-up, purification, and additional testing are still needed; some estimates project a $250 million market by 2032, and people with fructose intolerance or sensitive digestion may need caution.